Literature DB >> 2972557

The prevalence of serological markers, hepatitis B virus DNA and elevated serum amino transferase values in institutionalized mentally handicapped males and females: an epidemiological study of HBV infection in residents with Down's syndrome or other forms of mental deficiency.

T J van Ditzhuijsen1, F M Kleijnen, P J Rijntjes, A M van Loon, S H Yap.   

Abstract

Conventional HBV serological markers, as well as serum alanine amino transferase and hepatitis B virus DNA (HBV DNA) were studied in a population of 667 institutionalized mentally handicapped males and females and in 676 staff members. The role of Down's syndrome (DS), sex and age-related factors with respect to the prevalence of these markers was analyzed. A young age at admission was found as one of the important factors in the development of the chronic HBsAg carrier state in females. The well-known higher prevalence of HBsAg carriership in DS patients appeared to be restricted to males. Markers indicative of viral replication, HBeAg and HBV DNA, were also more prevalent in male than in female DS residents, or OMR residents. These findings indicate that the phase of active viral replication is prolonged in male HBsAg carriers with DS. However, only 66.7 per cent of HBV DNA-positive and 26.2 per cent of HBsAg-positive residents had abnormal serum alanine aminotransferase (ALT) values. In addition, more than 50 per cent of residents with elevated serum alanine amino transferase values were negative for HBV serological markers. We conclude that male DS residents are the main source of HBV infection in institutions for the mentally handicapped and that determination of ALT values is not very useful in identifying those HBsAg carriers capable of transmission the infection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2972557     DOI: 10.1007/bf00148923

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  23 in total

1.  Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I.

Authors:  P W Rigby; M Dieckmann; C Rhodes; P Berg
Journal:  J Mol Biol       Date:  1977-06-15       Impact factor: 5.469

2.  Australia antigen and Down's syndrome.

Authors:  A A Ferris; D B Pitt; I D Gust; J Kaldor
Journal:  Lancet       Date:  1972-01-01       Impact factor: 79.321

3.  Immune response to hepaitis virus type B in Down's syndrome and other mentally retarded patients.

Authors:  F B Hollinger; R K Goyal; T Hersh; H C Powell; R J Schulman; J L Malnick
Journal:  Am J Epidemiol       Date:  1972-04       Impact factor: 4.897

4.  Hepatitis and Down's syndrome.

Authors:  D L Madden; E B Matthew; D E Dietzman; R H Purcell; J L Sever; M Rostafinski; A Mata
Journal:  Am J Ment Defic       Date:  1976-01

5.  Discordance of hepatitis B e antigen/antibody and hepatitis B virus deoxyribonucleic acid in serum. Analysis of 1063 specimens.

Authors:  Y Matsuyama; M Omata; O Yokosuka; F Imazeki; Y Ito; K Okuda
Journal:  Gastroenterology       Date:  1985-11       Impact factor: 22.682

6.  Assay of hepatitis B virus genome titers in sera of infected subjects.

Authors:  E Zyzik; W H Gerlich; A Uy; H Köchel; R Thomssen
Journal:  Eur J Clin Microbiol       Date:  1986-06       Impact factor: 3.267

7.  Hepatitis B in a hospital for the mentally subnormal in southern England.

Authors:  J G Kingham; M McGuire; D H Paine; R Wright
Journal:  Br Med J       Date:  1978-08-26

8.  Hepatitis B virus DNA in the sera of HBsAg carriers: a marker of active hepatitis B virus replication in the liver.

Authors:  F Bonino; B Hoyer; J Nelson; R Engle; G Verme; J Gerin
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

9.  [Hepatitis B virus DNA as a marker of viral multiplication: comparison with HBe antigen and anti-HBe antibody].

Authors:  V Thiers; F Bouchardeau; A M Courouce; P Tiollais; C Brechot
Journal:  Presse Med       Date:  1986-06-28       Impact factor: 1.228

10.  Epidemiology of hepatitis B infection in institutionalized mentally retarded clients.

Authors:  S Lohiya; G Lohiya; S Caires
Journal:  Am J Public Health       Date:  1986-07       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.